The short version of modified GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
This was intended to demonstrate Rhodesia's continued loyalty to the Queen, but the use of the unmistakably British song at Rhodesian state occasions soon seemed "fairly ironic", as The Times put it. Salisbury started looking for a replacement anthem around the same time as its introduction of the new flag, and in 1974, after four years without an anthem ("God Save the Queen" was formally dropped in 1970), republican Rhodesia adopted "Rise, O Voices of Rhodesia", an anthem coupling original lyrics with the tune of Beethoven's "Ode to Joy". The country's head of state under the republican constitution was the President of Rhodesia, the first of whom was Dupont. State press censorship, which had been introduced on UDI, was lifted in early April 1968. Decimalisation occurred on 17 February 1970, two weeks before Rhodesia's reconstitution as a republic, with the new Rhodesian dollar replacing the pound at a rate of two dollars to each pound. Following the republic's formal declaration the next month, the Rhodesian military removed nomenclatural and symbolic references to the Crown—the Royal Rhodesian Air Force and Royal Rhodesia Regiment dropped their "Royal" prefixes after the Queen formally revoked them because of the declaration, new branch and regimental flags were designed, and the St Edward's Crown surmounting many regimental emblems was expunged in favour of the "Lion and Tusk", a motif from the coat of arms of the British South Africa Company that had been used in Rhodesian military symbolism since the 1890s.
After graduating, she accepted a postdoctoral fellowship at the Scripps Research Institute in La Jolla, California, where she worked under the guidance of Dr. Eric F. Johnson to study the regulation of CYP4A and CYP4F genes in mice. She studied what cellular pathways regulated fatty acid metabolism and how stress pathways influence the CYPs that metabolize lipids.
Gregory L. Verdine (born June 10, 1959) is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability. Verdine is the co-inventor with Christian Schafmeister of stapled peptides, a new class of drugs that combines the versatile binding properties of monoclonal antibodies with the cell-penetrating ability of small molecules. Verdine coined the term "drugging the undruggable" to describe the unique capabilities of stapled peptides. A close analog of a stapled peptide drug invented in the Verdine Lab, sulanemadlin (ALRN-6924), is a first-in-class dual MDM2/MDMX inhibitor currently in Phase II clinical development by Aileron Therapeutics, which he co-founded in 2005. FogPharma, founded in 2016, aims to further develop stapled peptide technology for therapeutic use. He has founded numerous other drug discovery companies, including six that are listed on the NASDAQ. His companies have succeeded in developing two FDA-approved drugs, romidepsin and paritaprevir, which are, respectively, an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs), and an acylsulfonamide inhibitor that is used to treat chronic hepatitis C.
Bektashism (Turkish: Bektaşîlik, Albanian: Bektashi) is a Sufi order of Islam that evolved in 13th-century western Anatolia and became widespread in the Ottoman Empire. It is named after the walī (saint) Haji Bektash Veli, with adherents called Bektashis. Origins of Haji Bektash's teachings can be traced back to the scholar Ahmad Yasawi of Turkestan. The highest title in Bektashi chain of succession is Dedebaba, followed by Halifebaba and Baba. The Bektashi Order of Tirana is currently led by Baba Mondi, recognized as the eighth Dedebaba, whose seat is at the order’s headquarters in Tirana, Albania. However, the Bektashi Order of Tirana is not recognized by Turkish Bektashis, specifying that Bektashi principles require Dedebaba to be in Anatolia, and the Albanian chain of succession never had Dedebabate. Bektashis believe in the ismah of the prophets and messengers and the Fourteen Infallibles: Muhammad, his daughter Fatima, and the Twelve Imams. In contrast to many Twelver Shia, Bektashis respect all of the Companions of Muhammad, including Abu Bakr, Umar, Uthman, Talha, Zubayr and Mu'awiya, with Ali considered the greatest of the Companions.
January 23: Law granting women the right to vote in elections for commercial courts. April 1: Law on mutual aid societies: these can notably be founded by women, and if the woman is married, she does not need her husband's involvement to do so. 1900
Sources: en.wikipedia.org
===== Guyana ===== In February 2024, president Lula announced he would visit Guyana and meet president Irfaan Ali to discuss topics such as the Essequiba border dispute with Venezuela and a potential hydro-power energy sharing agreement between Guyana and Brazil. On 28 February, Lula spoke at a CARICOM summit in Georgetown in which he said he intends Brazil to resume having diplomatic missions in the Caribbean nations. Lula added Brazil was making a monetary contribution to the Caribbean Development Bank.
=== Names === Mesocarb is the generic name of the drug and its INNTooltip International Nonproprietary Name. It is also known by the synonym fensidnimine as well as by the brand names Sydnocarb and Synocarb. The drug is additionally known by its developmental code name MLR-1017 (for Parkinson's disease).
It is estimated that 6.1 million tonnes of uranium exists in ores that are economically viable at US$130 per kg of uranium, while 35 million tonnes are classed as mineral resources (reasonable prospects for eventual economic extraction). Australia has 28% of the world's known uranium ore reserves and the world's largest single uranium deposit is located at the Olympic Dam Mine in South Australia. There is a significant reserve of uranium in Bakouma, a sub-prefecture in the prefecture of Mbomou in the Central African Republic. Some uranium also originates from dismantled nuclear weapons. For example, in 1993–2013 Russia supplied the United States with 15,000 tonnes of low-enriched uranium within the Megatons to Megawatts Program. An additional 4.6 billion tonnes of uranium are estimated to be dissolved in sea water (Japanese scientists in the 1980s showed that extraction of uranium from sea water using ion exchangers was technically feasible). There have been experiments to extract uranium from sea water, but the yield has been low due to the carbonate present in the water. In 2012, ORNL researchers announced the successful development of a new absorbent material dubbed HiCap which performs surface retention of solid or gas molecules, atoms or ions and also effectively removes toxic metals from water, according to results verified by researchers at Pacific Northwest National Laboratory.
=== EU risk assessments === In 2002 the EU Scientific Committee on Veterinary Measures relating to Public Health (SCVPH) claimed that the use of beef growth hormones posed a potential health risk, and in 2003 the EU enacted Directive 2003/74/EC to amend its ban, but the US and Canada objected that the EU had not met WTO standards for scientific risk assessment. The EC claimed that the hormones remain in the tissue, specifically 17-beta estradiol. However, the EC found no clear link to health risks in humans for the other five hormones. The EC reported that high amounts of hormones had been found in areas around dense cattle lots. This increase in hormones in groundwater affected waterways and nearby wild fish. Hormone contamination of North American waterways would not, however, have any health impacts on European consumers.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.